Aquestive Therapeutics, Inc. AQST Business Segments — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s business segments — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s business segments — revenue?
- Aquestive Therapeutics, Inc. (AQST) reported business segments — revenue of $14.45M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s business segments — revenue changed year-over-year?
- Aquestive Therapeutics, Inc.'s business segments — revenue increased by 65.7% year-over-year, from $8.72M to $14.45M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s business segments — revenue?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s business segments — revenue has grown at a -6.2% compound annual growth rate (CAGR), from $50.58M to $44.55M.
- What does business segments — revenue mean?
- Represents the total gross inflow of economic benefits arising from the ordinary operating activities of the reportable business segment. This metric reflects the market demand for the segment's specialized pharmaceutical products and services. It serves as a primary indicator of the segment's top-line growth and commercial success.